Orchestra BioMed price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Orchestra BioMed (OBIO) to $10 from $12 and keeps a Buy rating on the shares. The firm cites increased shares post the company’s recent financings for the target cut. However, it believes recenly published data demonstrate the utility of AVIM therapy in lowering blood pressure and improving cardiac function.